Track record · closed signal

AstraZeneca PLC (AZN) — closed signal from August 13, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 11, 2025 — +15.5% at the close.

Predicted vs. what happened

AZN price · publication thesis → realized outcomesplit-adjusted

$76.50 – $77.50Entry zone — fair-value band

$77.15Published — price the day we called it

$86.41Target — the price the thesis aimed for

$89.32Peak — highest point inside the window, not a realized return

$89.09Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 54 days.

At window close

+15.5%

realized, from the publication price to the last close inside the window

Peak gain

+15.8%

peak, from the publication price — not a realized return

S&P 500, same window

+6.2%

SPY over the identical days, dividend-adjusted

Window close

$89.09

last close inside the window, ended November 11, 2025

Peak price

$89.32

peak on November 11, 2025 — not a realized return

Days to target

The thesis — published August 13, 2025

Predicted growth

+12%

over the measurement window

Target price

$86.41

the price the thesis aimed for

Entry zone

$76.50 – $77.50

the fair-value band we waited for

Price at publication

$77.15

published August 13, 2025

Confidence

70%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

AstraZeneca's price action looks healthy, with strong buying interest and a rising recent average price. News that it is widening access to an EGFR lung cancer treatment in Ghana, plus a respected industry award, both lift confidence in execution. The core numbers are mixed, but its steady healthcare profile supports cautious buys on small dips for a gradual climb over the next 0-3 months.

Primary drivers

Buying looks strong and the recent average price is trending upward
Wider access to EGFR lung cancer therapy in Ghana supports growth
Industry award boosts trust and draws more investor interest near term
Large, steady pharma name that can hold up in choppy markets

How it played out

AZN: target reached in 54 days

Lyra published AZN at $77.15 on 2025-08-13 with an expected gain of 12%. The thesis pointed to strong buying, a rising recent average price, wider access to an EGFR lung cancer therapy in Ghana, an industry award, and the steadier profile of a large pharma company.

Inside the window, AZN reached the $86.41 target in 54 days. It kept rising and peaked at $89.32 on 2025-11-11, with a 15.8% peak gain. It ended the window at $89.09. The thesis played out.

What happened during the window

On 2025-11-06, AstraZeneca reported third-quarter revenue of $15.2 billion, up 10%, and kept its full-year forecasts. On the same date, Investors.com reported that oncology sales rose to $6.64 billion in the September quarter.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All AZN signals